Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder cancer ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

Durvalumab did not improve outcomes compared with cetuximab in patients with head and neck squamous cell carcinoma who are ...

根治性放化疗后免疫巩固治疗是 III 期不可切除非小细胞肺癌（NSCLC）患者当前的标准治疗模式[1]。然而，对于 EGFR 突变 III 期不可切除 NSCLC 患者，免疫巩固治疗可能无法带来预期的获益[2]。在此背景下，三代 EGFR-TKI 在 ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck ...

What are the symptoms of bladder cancer – and how is it treated? - The most common symptom of bladder cancer is blood in your ...

A 'game-changer' study found advanced bladder cancer patients treated with the drug durvalumab were a third less likely to ...